Terminated, withdrawn and suspended trials

reasonMatches

clinicaltrialsObservedShowing 51–100 of 137 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT03682055	Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive…	Phase 1 / Phase 2	terminated	Sep 24, 2018	Cullinan Therapeutics Inc.	Lack of efficacy	Efficacy / futility
NCT04644315	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T)	Phase 2	terminated	Nov 25, 2020	Hoffmann-La Roche	The data from this study is no longer needed.	Other (stated, no rule matched)
NCT02698111	Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma	Phase 1 / Phase 2	terminated	Mar 3, 2016	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Corporate policy adjustments	Other (stated, no rule matched)
NCT03544099	Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr…	Phase 2	terminated	Jun 1, 2018	National Health Research Institutes, Taiwan	Difficult to recruit Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA	Enrollment / accrual
NCT01332279	Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With…	Phase 1	withdrawn	Apr 11, 2011	Fox Chase Cancer Center	Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients.	Enrollment / accrual
NCT02582008	Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With…	Early Phase 1	terminated	Oct 21, 2015	Wake Forest University Health Sciences	Slow accrual	Enrollment / accrual
NCT02917629	ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer…	Phase 2	terminated	Sep 28, 2016	National Cancer Institute (NCI)	Low accrual combined with expiration of study drug	Enrollment / accrual
NCT05512767	A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage…	N/A	withdrawn	Aug 23, 2022	Mayo Clinic	PI retired and study not moving forward	Other (stated, no rule matched)
NCT05061940	This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status…	—	terminated	Sep 30, 2021	Repertoire Immune Medicines	Development program terminated	Other (stated, no rule matched)
NCT03506048	Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive…	Phase 2	terminated	Apr 23, 2018	Emory University	Study has been abandoned for lack of accrual	Enrollment / accrual
NCT01891695	OPSCC N0 Nodal Control With Reduced IMRT	N/A	terminated	Jul 3, 2013	Paul W. Read, MD	Study had very specific inclusion/exclusion criteria and difficult to recruit	Enrollment / accrual
NCT02363647	Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic…	N/A	terminated	Feb 16, 2015	Icahn School of Medicine at Mount Sinai	No Current Funding	Funding
NCT04831450	Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)	Phase 2	withdrawn	Apr 5, 2021	University of Miami	Investigator Decision	Investigator
NCT04001413	Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients	Phase 2	withdrawn	Jun 28, 2019	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Sponsor withdrew funding	Funding
NCT02289807	Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated…	N/A	withdrawn	Nov 13, 2014	Sun Yat-sen University	not stated	Not stated
NCT03838692	Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer	Phase 2	withdrawn	Feb 12, 2019	Antonio Fojo	Closed by sponsor	Other (stated, no rule matched)
NCT03131206	A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid…	Phase 1 / Phase 2	terminated	Apr 27, 2017	Dana-Farber Cancer Institute	Study closed due to slow accrual and lack of efficacy.	Efficacy / futility
NCT03630120	Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer	Phase 2	terminated	Aug 14, 2018	H. Lee Moffitt Cancer Center and Research Institute	Lack of efficacy	Efficacy / futility
NCT03463889	Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid…	Phase 2	terminated	Mar 13, 2018	University of California, San Francisco	Funding	Funding
NCT03390738	Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2…	Phase 2	withdrawn	Jan 4, 2018	The University of Hong Kong	Sponsor withdrew funding for Nivolumab	Funding
NCT02177838	Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck…	N/A	terminated	Jun 30, 2014	Rutgers, The State University of New Jersey	Slow accrual	Enrollment / accrual
NCT01707056	The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid…	N/A	withdrawn	Oct 15, 2012	Medstar Health Research Institute	not stated	Not stated
NCT04231864	Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic…	Phase 2	withdrawn	Jan 18, 2020	Alain Algazi	Feasibility	Other (stated, no rule matched)
NCT02709889	Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors	Phase 1 / Phase 2	terminated	Mar 16, 2016	AbbVie	Strategic considerations	Sponsor / business decision
NCT00603941	A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel	Phase 1 / Phase 2	terminated	Jan 29, 2008	Daiichi Sankyo	Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated…	Safety / toxicity
NCT04106843	Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or…	Phase 2	withdrawn	Sep 27, 2019	M.D. Anderson Cancer Center	No Participants Registered	Other (stated, no rule matched)
NCT02464137	HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer(HYDRA)	Phase 1	terminated	Jun 8, 2015	University of Texas Southwestern Medical Center	unexpected toxicities	Safety / toxicity
NCT01249443	Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors…	Phase 1	terminated	Nov 29, 2010	AIDS Malignancy Consortium	Inadequate accrual rate	Enrollment / accrual
NCT00181220	Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal…	Phase 1	withdrawn	Sep 16, 2005	Johns Hopkins University	PI left JHU and is not able to be reached for updates	Investigator
NCT00367718	Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma	Phase 2	withdrawn	Aug 23, 2006	Johns Hopkins University	PI left JHU and is not able to be reached for updates	Investigator
NCT01192815	Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the…	Phase 2	terminated	Sep 1, 2010	Case Comprehensive Cancer Center	Funding unavailable	Funding
NCT02236936	Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the…(AGMT_HNO_PN)	Phase 3	terminated	Sep 11, 2014	Arbeitsgemeinschaft medikamentoese Tumortherapie	Study stopped due to low recruitment	Enrollment / accrual
NCT02569788	Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma	Phase 1 / Phase 2	terminated	Oct 7, 2015	Shanghai Proton and Heavy Ion Center	Slow accrual of patients.	Enrollment / accrual
NCT02801487	Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally…	Phase 1 / Phase 2	terminated	Jun 15, 2016	Shanghai Proton and Heavy Ion Center	Slow accrual of patients.	Enrollment / accrual
NCT00582712	An Initial Study of Lithium in Patients With Medullary Thyroid Cancer	Phase 2	terminated	Dec 28, 2007	University of Wisconsin, Madison	Budget/Funding	Funding
NCT01974284	Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma	N/A	terminated	Nov 1, 2013	Yale University	Lack of patient enrollment	Enrollment / accrual
NCT02657369	A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)	Phase 2	terminated	Jan 15, 2016	Eisai Inc.	Overall response rate was 3% (only 1 out of 33 participants had confirmed PR).	Other (stated, no rule matched)
NCT01230476	Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally…	Phase 2	terminated	Oct 29, 2010	University of Malaya	not stated	Not stated
NCT02062632	Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer…	Phase 2	terminated	Feb 14, 2014	Mayo Clinic	Poor accrual	Enrollment / accrual
NCT02789189	Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic…	Phase 2	terminated	Jun 2, 2016	Sun Yat-sen University	not stated	Not stated
NCT03575234	Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or…	Phase 1	withdrawn	Jul 2, 2018	Emory University	funding and drug were withdrawn	Funding
NCT03611205	Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced…	N/A	withdrawn	Aug 2, 2018	Ohio State University Comprehensive Cancer Center	PI decision	Other (stated, no rule matched)
NCT02289144	Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer	Phase 2	withdrawn	Nov 13, 2014	University of Texas Southwestern Medical Center	study was on hold for protocol redesign; decided to not move forward with study.	Other (stated, no rule matched)
NCT02706691	BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer	Phase 2	terminated	Mar 11, 2016	University of Chicago	Study stopped due to poor enrollment.	Enrollment / accrual
NCT00484601	Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma	Phase 2	terminated	Jun 11, 2007	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Low accrual.	Enrollment / accrual
NCT03049358	Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With…	N/A	terminated	Feb 10, 2017	Stanford University	Accrual factor	Enrollment / accrual
NCT02388932	Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced…	N/A	terminated	Mar 17, 2015	Case Comprehensive Cancer Center	Slow Accrual	Enrollment / accrual
NCT00923247	A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome…	Phase 1 / Phase 2	terminated	Jun 18, 2009	National Cancer Institute (NCI)	Terminated due to slow accrual,primary endpoint reached \& investigator left NIH.	Investigator
NCT01164566	Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer…	N/A	terminated	Jul 16, 2010	Wake Forest University Health Sciences	Inadequate Recruitment	Enrollment / accrual
NCT02552550	Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx	—	terminated	Sep 17, 2015	Centre Hospitalier Universitaire de Saint Etienne	rate of inclusion too low	Other (stated, no rule matched)

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 22 days agoSource updated Aug 15, 2023source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules